Vyome Holdings Inc (HIND) Stock Price, Quote & News

Company Profile

Vyome Holdings Inc., a clinical-stage healthcare company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States and global markets. The company was founded in 2017 and is based in Cambridge, Massachusetts.

Industry: Biotechnology

Sector: Healthcare

Phone: 973-832-8147

Website: www.vyometx.com

Address:

Harvard Square, One Mifflin Place Suite 400, Cambridge, United States

muriokurt Oct. 20 at 3:02 PM

$HIND @KKG2020 Any word on $LICH bro? Been a long "month" since the PR...

0 · Reply

drwaz Oct. 15 at 12:37 PM

$HIND 👀

0 · Reply

MrStealYoMoney Oct. 14 at 5:12 AM

$HIND $SPY wow

0 · Reply

MrStealYoMoney Oct. 14 at 4:29 AM

$CVNA $HIND hmm

1 · Reply

MrStealYoMoney Oct. 14 at 4:28 AM

$HIND $SPY

0 · Reply

MrStealYoMoney Oct. 14 at 4:27 AM

$HIND

0 · Reply

MilsLearning Oct. 13 at 10:00 AM

$HIND "L"ets "F" "S"horts 🔥🩳🔥🩳🔥🖕🔥🩳🔥🖕🩳🔥✅ Ever get bullied??? Trading stocks?? Me too!!! Get the bullies out of the schools 🏫 The IPO Foreign Meme movement ***LFS***

0 · Reply

knowithall Oct. 13 at 2:32 AM

$HIND Looks like they diluted just as it was starting to move up. Dumb of them to kill the momentum, even if it is mild dilution. They obviously needed some cash.

1 · Reply

_CircuitBreaker Oct. 9 at 10:49 PM

Keep a close watch on CMCT! $BGMS $ALZN $XHG $HIND

0 · Reply

_CircuitBreaker Oct. 9 at 10:23 PM

Keep a close watch on CMCT! $HIND $NAOV $WATT $VERU V

0 · Reply

Vyome Holdings Acquires MIT AI Spinout Oculo Health

Sep 17, 2025, 7:00 AM EDT - 5 weeks ago

Vyome Presents Strong Data Showing Topical VT-1908 is an Effective Treatment for Uveitis, Opening Up a $3B Addressable Market Opportunity

Sep 9, 2025, 8:30 AM EDT - 6 weeks ago

Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies

Sep 4, 2025, 8:30 AM EDT - 7 weeks ago

Vyome Holdings Announces Positive Interim Data from Phase 2 Study of VT-1953 in Malignant Fungating Wounds (MFW) and Provides Update on MFW market opportunity

Aug 21, 2025, 7:00 AM EDT - 2 months ago

Vyome Signs MoU with Embryyo, India's Leading Medical Device Innovation Studio

Aug 18, 2025, 8:30 AM EDT - 2 months ago

Vyome Announces Strategic Review of Livechain (OTCID: LICH)

Aug 15, 2025, 8:00 AM EDT - 2 months ago

Vyome To Mark First Day of Trading as HIND with Nasdaq Opening Bell

Aug 14, 2025, 7:18 PM EDT - 2 months ago

Vyome closes Merger Transaction, Will Trade on Nasdaq as HIND Tomorrow

RSLS

Aug 13, 2025, 11:50 AM EDT - 2 months ago

Vyome Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HIND

RSLS

Aug 12, 2025, 9:48 AM EDT - 2 months ago

Vyome Announces New Board of Directors with Deep MIT and AI Ties

RSLS

Aug 7, 2025, 5:01 PM EDT - 2 months ago

ReShape Lifesciences Announces Shareholder Approval of Merger with Vyome Therapeutics

RSLS

Jul 24, 2025, 4:39 PM EDT - 3 months ago

ReShape Lifesciences® Announces Partial Adjournment of Special Meeting of Stockholders

RSLS

Jul 22, 2025, 8:31 AM EDT - 3 months ago

ReShape Lifesciences® to Host Inaugural Lap-Band® Surgeon Summit

RSLS

Jul 21, 2025, 2:10 PM EDT - 3 months ago

ReShape Lifesciences® to Host Special Meeting of Stockholders on July 24, 2025

RSLS

Jul 1, 2025, 8:31 AM EDT - 4 months ago

ReShape Lifesciences® Granted U.S. Patent Related to an Intragastric Balloon System

RSLS

Jun 27, 2025, 9:01 AM EDT - 4 months ago

ReShape Lifesciences® Regains Compliance with Nasdaq Minimum Stockholders Equity Requirement

RSLS

Jun 26, 2025, 8:31 AM EDT - 4 months ago

ReShape Lifesciences® Announces Strategic Cost Reductions and Provides Update on the Merger Agreement with Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys

RSLS

Jun 25, 2025, 8:31 AM EDT - 4 months ago

ReShape Lifesciences® Granted Key International Patent in Australia for Its Proprietary Diabetes Neuromodulation Technology

RSLS

Jun 12, 2025, 8:25 AM EDT - 4 months ago

ReShape Lifesciences® Signs Exclusive Distribution Agreement with Recon Supply to Access the VA and DoD Markets

RSLS

Jun 9, 2025, 9:00 AM EDT - 4 months ago

ReShape Lifesciences® Announces Pricing of $2.6 Million Public Offering

RSLS

Jun 3, 2025, 8:31 AM EDT - 5 months ago

ReShape Lifesciences® Announces EU MDR Certification for Entire European and United Kingdom Product Portfolio

RSLS

May 21, 2025, 8:31 AM EDT - 5 months ago

ReShape Lifesciences® Reports First Quarter Ended March 31, 2025 Financial Results and Provides Corporate Update

RSLS

May 12, 2025, 8:32 AM EDT - 5 months ago

Orla Mining, ReShape Lifesciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session

ORLA RSLS

May 7, 2025, 8:31 AM EDT - 6 months ago

ReShape Lifesciences Announces 1-for-25 Reverse Stock Split

RSLS

May 2, 2025, 8:31 AM EDT - 6 months ago

ReShape Lifesciences® Presents Pre-clinical Data on Its Proprietary Diabetes Neuromodulation Device at the 12th Annual Minnesota Neuromodulation Symposium

RSLS

Apr 28, 2025, 8:31 AM EDT - 6 months ago

ReShape Lifesciences® Receives Notice of Allowance for Key U.S. Patent Related to an Intragastric Balloon System

RSLS

Apr 21, 2025, 8:31 AM EDT - 6 months ago

ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology

RSLS

Apr 10, 2025, 5:54 PM EDT - 7 months ago

ReShape Lifesciences Inc. (RSLS) Earnings Highlights and Strategic Business Update Conference (Transcript)

RSLS

Apr 9, 2025, 4:05 PM EDT - 7 months ago

ReShape Lifesciences® Partners with Motion Informatics to Bring AI-Driven Neurorehabilitation Technology to the U.S. Market

RSLS

Apr 7, 2025, 4:05 PM EDT - 7 months ago

ReShape Lifesciences® Reports Year Ended December 31, 2024 Financial Results and Provides Corporate Update

RSLS

Mar 21, 2025, 11:35 AM EDT - 7 months ago

RESHAPE LIFESCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ReShape Lifesciences Inc. - RSLS

RSLS

Mar 10, 2025, 8:31 AM EDT - 8 months ago

ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology

RSLS

Feb 25, 2025, 8:31 AM EST - 8 months ago

ReShape Lifesciences® Signs Distribution Agreement in Canada With Liaison Medical for its Next-Generation Lap-Band® 2.0 FLEX

RSLS

Feb 15, 2025, 11:17 PM EST - 8 months ago

ReShape Lifesciences® Announces Pricing of Upsized $6.0 Million Public Offering

RSLS

Feb 3, 2025, 8:31 AM EST - 9 months ago

ReShape Lifesciences® Granted Key International Patent in Israel for Its Proprietary Diabetes Neuromodulation Technology

RSLS

Jan 13, 2025, 8:31 AM EST - 10 months ago

ReShape Lifesciences® Provides Update on Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys

RSLS

Nov 14, 2024, 7:43 PM EST - 1 year ago

ReShape Lifesciences Inc. (RSLS) Q3 2024 Earnings Call Transcript

RSLS

Nov 12, 2024, 4:05 PM EST - 1 year ago

ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

RSLS

Nov 12, 2024, 8:31 AM EST - 1 year ago

ReShape Lifesciences® Receives Health Canada Approval for its Next-Generation Lap-Band® 2.0 FLEX

RSLS

Nov 11, 2024, 8:31 AM EST - 1 year ago

ReShape Lifesciences® Receives NIH Supplementary Grant with the University of Southern California's Center for Autonomic Nerve Recording and Stimulation Systems (CARSS) to Further Develop Next-Generation Electrodes for ReShape's Proprietary Diabetes Bloc-Stim Neuromodulation™ Technology

RSLS

Sep 19, 2024, 8:31 AM EDT - 1 year ago

ReShape Lifesciences Announces 1-for-58 Reverse Stock Split

RSLS

Aug 15, 2024, 8:42 PM EDT - 1 year ago

ReShape Lifesciences Inc. (RSLS) Q2 2024 Earnings Call Transcript

RSLS

Aug 13, 2024, 8:31 AM EDT - 1 year ago

ReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update

RSLS

Jul 19, 2024, 8:05 AM EDT - 1 year ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CHUY, RSLS on Behalf of Shareholders

CHUY RSLS

Jul 9, 2024, 12:13 PM EDT - 1 year ago

Vyome to go public and trade on the Nasdaq Capital Market under the ticker symbol “HIND”

RSLS

Jul 9, 2024, 8:31 AM EDT - 1 year ago

ReShape Lifesciences® Enters Into Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys

RSLS

May 17, 2024, 8:57 PM EDT - 1 year ago

ReShape Lifesciences, Inc. (RSLS) Q1 2024 Earnings Call Transcript

RSLS

May 15, 2024, 4:05 PM EDT - 1 year ago

ReShape Lifesciences® Reports First Quarter Ended March 31, 2024 Financial Results and Provides Corporate Update

RSLS

May 14, 2024, 8:31 AM EDT - 1 year ago

ReShape Lifesciences® to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update

RSLS

muriokurt Oct. 20 at 3:02 PM

$HIND @KKG2020 Any word on $LICH bro? Been a long "month" since the PR...

0 · Reply

drwaz Oct. 15 at 12:37 PM

$HIND 👀

0 · Reply

MrStealYoMoney Oct. 14 at 5:12 AM

$HIND $SPY wow

0 · Reply

MrStealYoMoney Oct. 14 at 4:29 AM

$CVNA $HIND hmm

1 · Reply

MrStealYoMoney Oct. 14 at 4:28 AM

$HIND $SPY

0 · Reply

MrStealYoMoney Oct. 14 at 4:27 AM

$HIND

0 · Reply

MilsLearning Oct. 13 at 10:00 AM

0 · Reply

knowithall Oct. 13 at 2:32 AM

$HIND Looks like they diluted just as it was starting to move up. Dumb of them to kill the momentum, even if it is mild dilution. They obviously needed some cash.

1 · Reply

_CircuitBreaker Oct. 9 at 10:49 PM

Keep a close watch on CMCT! $BGMS $ALZN $XHG $HIND

0 · Reply

_CircuitBreaker Oct. 9 at 10:23 PM

Keep a close watch on CMCT! $HIND $NAOV $WATT $VERU V

0 · Reply

VyomeInc1 Oct. 9 at 3:28 PM

$HIND 7+ weeks since listing. Vyome Holdings is progressing well — key initiatives advancing, milestones in motion, and clear updates through frequent press releases. Management & Board focused on disciplined execution & long-term value, fully capitalized thorough 2026. #Biotech #Execution #Strategy #investing

2 · Reply

VyomeInc1 Oct. 8 at 5:27 PM

$HIND Vyome Holdings management, board, and key insiders hold locked-up shares, signaling long-term alignment. We prioritize cost-efficient operations and dilution awareness to support shareholder value over time. We’re building to endure and working on creating a potential long term value to shareholders. #LongTermFocus #ShareholderValue #BiotechStrategy

0 · Reply

TA_Kongen Oct. 8 at 9:14 AM

$XBIO $BGLC $MLEC $GTBP $HIND Biotechs with potential to move part 2.

0 · Reply

movam Oct. 8 at 12:24 AM

$HIND Looking for $9 to $10 run this time!

0 · Reply

movam Oct. 7 at 11:13 PM

$HIND Last high was $15. Let’s see what she does thus time!

0 · Reply

SaluteYourShorts Oct. 7 at 7:34 PM

$HIND super turd... stop trying to pump this stock, it is one of the worst known in existance.

1 · Reply

knowithall Oct. 7 at 7:33 PM

$HIND Keep an eye on after hours. This is ready to run hard IMO.

0 · Reply

VyomeInc1 Oct. 7 at 6:56 PM

$HIND We @Vyomeinc $HIND focus on US-India Innovation Corridor edge, potential orphan-pathway focus-smaller trials, smarter development, lean spend. Runway fully funded to end-2026, dilution conscious. Building durable biotech, AI-healthcare company. #BiotechInvest #OrphanSpeed #biotech

1 · Reply

AlienRabbit Oct. 7 at 6:49 PM

$HIND bounced from vwap, just need a little of attention

0 · Reply

Shane393 Oct. 7 at 6:31 PM

$HIND time to short this scam one more time.

1 · Reply

s3mi Oct. 7 at 6:00 PM

$HIND can pull a $NITO too also in $BURU

0 · Reply

knowithall Oct. 7 at 5:09 PM

$HIND Once it breaks 6.44 resistance we're off to the races! $BQ $GLTO

0 · Reply

Market Cap	20.23M
Revenue (ttm)	8.01M
Net Income (ttm)	-7.13M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-89.01%
Debt to Equity Ratio	0.00

Volume	27,200
Avg Vol	398,934
Day's Range	N/A - N/A
Shares Out	3.66M
Stochastic %K	79%
Beta	1.05
Analysts	Strong Sell
Price Target	$15.00